










# Coronavirus Disease 2019 in Autoimmune Hepatitis: A Lesson From Immunosuppressed Patients

Alessio Gerussi <sup>1,2</sup>, Cristina Rigamonti <sup>3,4</sup>, Chiara Elia,<sup>5</sup> Nora Cazzagon <sup>6,7</sup>, Annarosa Floreani <sup>6,8</sup>, Roberta Pozzi,<sup>9</sup> Pietro Pozzoni,<sup>9</sup> Ernesto Claar,<sup>10</sup> Luisa Pasulo <sup>11</sup>, Stefano Fagioli <sup>11</sup>, Laura Cristoferi <sup>1,2</sup>, Marco Carbone <sup>1,2</sup> and Pietro Invernizzi <sup>1,2</sup>

Chronic immunosuppression is associated with increased and more severe viral infections. However, little is known about the association between immunosuppression and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Our aim was to describe the clinical course of patients with immunosuppressed autoimmune hepatitis (AIH) during coronavirus disease 2019 (COVID-19) infection in Italy. Our study is a case series of patients with AIH treated with immunosuppression, who tested positive for SARS-CoV-2 in March 2020 during the outbreak of COVID-19. Ten patients from seven different hospitals in Italy were diagnosed with COVID-19 during the outbreak of SARS-CoV-2 in March 2020. Seven subjects were female (70%), and age ranged from 27 to 73 years. Before the onset of SARS-CoV-2 infection, all patients were taking immunosuppressive therapy for AIH, and eight of them were on biochemical remission. Two other patients had recent acute onset of their AIH, and consequently started high-dose steroids, as per induction protocol. All patients had a respiratory syndrome and a positive nasal swab for SARS-CoV-2. Five patients developed a computed tomography–confirmed COVID-19 pneumonia. Six subjects received a combination of antiretroviral and antimalarial drugs. In seven patients, the dosage of immunosuppressive medication was changed. Liver enzymes were repeated during SARS-CoV-2 infection in all hospitalized cases; they remained within the normal range in all cases, and improved in the two acute cases treated with high-dose steroids. The clinical outcome was comparable to the reported cases occurring in non-immunosuppressed subjects. *Conclusion:* Patients under immunosuppressive therapy for AIH developing COVID-19 show a disease course presumptively similar to that reported in the non-immunosuppressed population. These data might aid in medical decisions when dealing with SARS-CoV-2 infection in immunocompromised patients. (*Hepatology Communications* 2020;4:1257-1262).

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a pandemic infection causing coronavirus disease 2019 (COVID-19), and Italy is one of the mostly affected countries worldwide.<sup>(1)</sup> The impact of COVID-19 in patients with autoimmune liver disease treated with immunosuppressive

therapy has not been described so far. Primarily, concerns have been raised for immunosuppressed patients, particularly those with autoimmune hepatitis (AIH), due to the possibility of decompensation of liver disease, or to an unfavorable course of SARS-CoV-2 infection. AIH is a rare liver disease and a prototypical

*Abbreviations:* AIH, autoimmune hepatitis; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome.

Received April 16, 2020; accepted June 3, 2020.

Supported by the Biocompatible Nano-assemblies to Increase the Safety and the Efficacy of Steroid Treatment Against Liver Inflammation (Grant/Award Number GR-2018-12367794) and the Role of Auto-reactive Hepatic Natural Killer Cells in the Pathogenesis of Primary Biliary Cholangitis (Grant/Award Number PE-2016-02363915).

© 2020 The Authors. *Hepatology Communications* published by Wiley Periodicals LLC on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

View this article online at [wileyonlinelibrary.com](http://wileyonlinelibrary.com).

DOI 10.1002/hep4.1557

Potential conflict of interest: Dr. Cazzagon consults for Intercept. Dr. Floreani consults for Intercept. Dr. Fagioli advises and is on the speakers' bureau for Gilead, AbbVie, MSD, Novartis, and Bayer. He is on the speakers' bureau for Astellas, Intercept, and Kedrion. Dr. Invernizzi consults and received grants from Intercept. He received grants from Gilead.

example of chronic autoimmune condition requiring maintenance immunosuppression.<sup>(2)</sup> Stopping immunosuppression is associated with almost inevitable relapse of the disease.<sup>(3)</sup> Viral infections in an immunocompromised host are more frequent than in the general population, and have the ability to cause severe disease at much higher rates than in the healthy population.<sup>(4,5)</sup> Nonetheless, data from previous outbreaks of Coronavirus infections, like severe acute respiratory syndrome and Middle East respiratory syndrome, did not report a higher risk of morbidity and mortality related to immunosuppression.<sup>(6)</sup> Therefore, there is uncertainty on how to manage immunosuppression therapy during the SARS-CoV-2 pandemic.

This report describes the clinical course of ten patients with AIH who developed COVID-19 in Italy. Patients provided informed consent for the inclusion in this study, and the diagnostic procedures were conducted in accordance with institutional guidelines.

## Case Series

We contacted 67 large Italian liver units (24 in Lombardy) during the outbreak of SARS-CoV-2, asking about cases of COVID-19 that occurred in patients with AIH followed up at these centers.

Ten patients with AIH from seven different hospitals in Italy, located primarily in the Lombardy region, were diagnosed with COVID-19 during the outbreak of SARS-CoV-2 in March 2020 (Table 1). Seven subjects were female (70%), and age ranged from 27 to 73 years. Cirrhosis was present in four cases (40%),

and patient 6 had decompensated cirrhosis (Child-Pugh B) with history of previous episodes of ascites and hepatic encephalopathy.

Before the onset of COVID-19, all patients were taking immunosuppressive therapy with different dosages. All but one (patient 8) were on steroids (prednisone), and four (40%) were on azathioprine; patient 1 was on triple immunosuppressive regimen due to difficult-to-treat AIH. The immunosuppression regimen was stable in eight patients who were on biochemical remission at recent evaluation. Two other patients (patients 2 and 4) had an acute onset of AIH and were under high-dose steroids, as per induction protocol, at the time of SARS-CoV-2 infection.

All cases were symptomatic for respiratory syndrome and positive for SARS-CoV-2 at nasal swab; four cases were managed at home under compulsory quarantine. Among those managed at home, one patient was afebrile and had persistent cough and headache; the others were febrile and had cough as main symptom. Among the six hospitalized subjects, five developed a computed tomography–confirmed COVID-19 pneumonia. Three patients were treated with continuous positive airway pressure support for hypoxemic respiratory failure.

All subjects received a combination of an antiretroviral drug (either lopinavir/ritonavir or darunavir/cobicistat) with an antimalarial medication (either hydroxychloroquine or chloroquine); two cases were also treated with azithromycin. Empirical therapies for SARS-CoV-2 infection were in line with recommendations given by the infectious disease service of each hospital.

In seven patients, the dosage of immunosuppressive therapy was changed. Prednisone regimens were

### ARTICLE INFORMATION:

From the <sup>1</sup>Division of Gastroenterology and Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; <sup>2</sup>European Reference Network on Hepatological Diseases, San Gerardo Hospital, Monza, Italy; <sup>3</sup>Department of Translational Medicine, Università del Piemonte Orientale UPO, Novara, Italy; <sup>4</sup>Division of Internal Medicine, AOU Maggiore della Carità, Novara, Italy; <sup>5</sup>Gastroenterology Unit, Cardinal Massaia Hospital, Asti, Italy; <sup>6</sup>Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; <sup>7</sup>European Reference Network on Hepatological Diseases, Gastroenterology Unit, Azienda Ospedaliera Universitaria Padova, Padova, Italy; <sup>8</sup>IRCCS Negrar, Verona, Italy; <sup>9</sup>Internal Medicine Unit, ASST Lecco, Lecco, Italy; <sup>10</sup>Liver Unit, Evangelico Betania Hospital, Napoli, Italy; <sup>11</sup>Gastroenterology, Hepatology and Liver Transplantation Unit, Department of Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy.

### ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:

Pietro Invernizzi, M.D., Ph.D.  
Division of Gastroenterology and Center for Autoimmune Liver Diseases  
Department of Medicine and Surgery  
University of Milano-Bicocca

Via Cadore 48  
20900 Monza, Italy  
E-mail: [pietro.invernizzi@unimib.it](mailto:pietro.invernizzi@unimib.it)  
Tel.: +39 039 233 2187

TABLE 1. CLINICAL COURSE AND LABORATORY RESULTS

Patient ID	1	2	3	4	5	6	7	8	9	10
Age, years	27	55	45	55	53	68	55	65	68	73
Sex	F	M	F	M	F	F	F	M	F	F
Cirrhosis	Yes	No	No	Yes	Yes	Yes	No	No	No	No
Date of previous labs	Feb 17, 2020	Feb 14, 2020	Jan 23, 2020	Mar 9, 2020	Mar 26, 2019	Mar 4, 2020	Feb 1, 2020	Mar 15, 2020	Feb 28, 2020	Feb 20, 2020
AST, U/L	21	37	22	317	34	N/A	37	19	50	27
ALT, U/L	17.4	52	24	497	36	21	19	14	30	16
T Bil, mg/dl	0.4	1.0	1.0	2.6	1.0	0.9	1.6	0.6	1.0	N/A
Alb, g/dl	3.9	3.5	4.2	3.0	3.7	N/A	4.3	N/A	N/A	3.9
PLT, x 10 <sup>3</sup> /μL	146	255	314	124	177	93	159	N/A	N/A	215
Lymph, x 10 <sup>9</sup> /L	N/A	N/A	2.6	2.5	2.8	N/A	N/A	2.1	N/A	N/A
IgG, g/L	14.0	10.0	11.6	33.7	7.8	N/A	N/A	N/A	N/A	N/A
P pre	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes
Dose, mg	10	40	10	60	10	5	5	No	25	20
AZA pre	Yes	Yes	No	No	No	No	Yes	No	No	Yes
Dose, mg	50	50	No	No	No	No	100	No	No	75
Other drugs for AIH	Tac							MMF		No
Dose	1 mg every 12 hours							1,500 mg/day		No
Clinical course	Mar 7, 2020	Mar 6, 2020	Mar 5, 2020	Mar 17, 2020	Mar 1, 2020	Mar 15, 2020	Mar 18, 2020	Mar 11, 2020	Mar 1, 2020	Mar 1, 2020
symptoms onset	Cough, headache	Fever	Fever, cough	Fever, cough	Cough, fever, diarrhea	Cough, fever	Cough, fever	Fever, cough	Fever, cough	Fever, cough
Clinical features	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Swab positive for SARS-CoV-2	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Managed at home or at hospital	Home	Hospital	Hospital	Hospital	Hospital	Hospital	Home	Hospital	Home	Home
Pneumonia	N/A	Yes	Yes	Yes	No	Yes	N/A	Yes	N/A	N/A
Respiratory failure	No	No	Yes	No	No	Yes	No	Yes	No	No
Any change of drugs for AIH	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	No
If yes, which drug was changed?	P, AZa	P, AZa		P	P	P		MMF	P	
Dose change	P ↓ 7.5 mg/day, Aza X	P ↓ 30 mg/day, Aza X		P ↓ 40 mg/day	P ↑	P ↑ 25 mg/day		MMF ↓ 1,000 mg/day	Self-stopped	
Date of change	Mar 15, 2020	Mar 7, 2020		Mar 20, 2020	Mar 10, 2020	Mar 26, 2020		Mar 26, 2020	Feb 3, 2020	
Date of return to previous dose	Not yet	Not yet		Not yet	Mar 23, 2020	Not yet		Not yet	May 16, 2020 <sup>f</sup>	
Drugs for COVID-19	/	H, L/R, Azi	H, L/R	H, D/C	C, L/R	H, L/R	/	H, L/R, Azi	/	/

TABLE 1. Continued

Patient ID	1	2	3	4	5	6	7	8	9	10
Repeated liver enzymes during COVID-19	No*	Yes	Yes	Yes	Yes	Yes	No*	Yes	No*	No*
AST, U/L		39	23	82	98	34		22		
ALT, U/L		38	17	101	46	31		11		
T Bil, mg/dL		1.5	0.9	3.2	1.0	0.8		0.7		
Alb, g/dL		3.5	3.6	2.6	3.4	N/A		N/A		
Lymph, $\times 10^9/L$		N/A	0.7	0.6	0.3	N/A		0.5		
Follow-up labs	Apr 27, 2020	May 19, 2020	Mar 20, 2020	Mar 26, 2020	Mar 18, 2020	No	No	Apr 1, 2020	May 15, 2020	May 12, 2020
AST, U/L	25	39	30	66	36			27	600	11
ALT, U/L	34	39	30	89	27			14	599	17
T Bil, mg/dL	0.6	0.7	N/A	2.2	1			0.4	2.4	39
Alb, g/dL		37	N/A	N/A	34					
Lymph, $\times 10^9/L$	1.6	3.5	1.5	3.9	1.6			1.0	1.4	
Current status (as of May 21, 2020)	A	A	A	A	A	Exitus on Apr 1, 2020	A	A	A	A

SI conversion factors: to convert platelet count to  $\times 10^9$  per liter, multiply by 1.

\*Blood exams not repeated due to restrictions related to compulsory quarantine at home.

†Restarted with Prednisone 50 mg for the treatment of the relapse of AIH.

Abbreviations: A, asymptomatic; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Aza, azathioprine; Azi, azithromycin; C, chloroquine; D/C, darunavir/cobicistat; F, female; H, hydrochloroquine; IgG, immunoglobulin G; L/R, lopinavir/ritonavir; Lymph, lymphocytes; M, male; MMF, mycophenolate; N/A, not applicable; P, prednisone; PLT, platelets; T Bil, total bilirubin; TAC, tacrolimus; Y, years.

heterogeneously managed: in three cases doses were reduced, while patient 9 self-stopped it. Patients 2 and 4 were given high-dose corticosteroids to induce remission and tapering the dosage thereafter. In two cases, only the prednisone regimen was increased. Azathioprine was stopped in patients 1 and 2; in patient 1, prednisone was reduced from 10 mg/day to 7.5 mg/day, while tacrolimus was maintained at the same dose.

Liver enzymes were repeated during SARS-CoV-2 infection in all hospitalized cases, and remained within the normal range in all cases except for patients 2 and 4, in whom liver function tests dramatically improved. In four hospitalized cases, data about lymphocyte count were available; all patients experienced acute lymphopenia (severe in two subjects), which was not present before admission and fully reverted after COVID-19.

At the time of submission, nine patients are still alive and asymptomatic, and patient 6 has died. Patient 9, who had previously self-stopped immunosuppression with steroids, has experienced a relapse of AIH and is now being treated with prednisone 50 mg/day.

## Discussion

We report here the first ten cases of COVID-19 occurred in patients with AIH under immunosuppressive treatment. With the limitation of the short follow-up and the lack of a control group of patients without AIH, we do report a somehow unremarkable COVID-19 disease course despite ongoing immunosuppression. Remarkably, one patient went through COVID-19 without developing pneumonia, despite the combination of compensated cirrhosis and acute AIH, with consequent need for high-dose induction with steroids. The death event occurred in the frailest patient included in the cohort (patient 6), who already had decompensated cirrhosis, which is associated with significant morbidity and mortality.<sup>(7)</sup> Moreover, we believe that pre-emptive strategies of reduction of immunosuppression during COVID-19 can be potentially harmful, as suggested by the disease course of patient 9, who self-stopped steroid treatment and relapsed after SARS-CoV-2 infection. There is growing evidence that part of the morbidity of COVID-19 is due to the

hyperinflammation and cytokine storm,<sup>(8)</sup> as supported by data from China, which showed that high levels of IL-6 are associated with increased mortality<sup>(9)</sup> and the supposed beneficial effects of immunomodulators (tocilizumab and other IL-6 blockers<sup>(10)</sup> such as baricitinib<sup>(11)</sup>). Recently, a systems pharmacology-based network medicine platform identified mercaptopurine as one of the potential drugs to treat COVID-19.<sup>(12)</sup> Mercaptopurine, also known as 6-mercaptopurine, is a metabolite of azathioprine, and together with azathioprine belongs to the group of thiopurines, the most commonly used drugs for AIH maintenance. Thus, one could speculate that empirical strategies of reduction of immunosuppression in patients affected by chronic autoimmune diseases might be even harmful if immunosuppression might at least counterbalance COVID-19-driven hyperinflammation.

One of the known side effects of thiopurines is lymphopenia, which is often mild to moderate and considered a parameter of effective immunosuppression.<sup>(13)</sup> Yet, lymphopenia is known to predispose to viral infections, and thiopurines have been linked with increased incidence of opportunistic viral infections in patients with inflammatory bowel disease.<sup>(4)</sup> Data from the Wuhan experience have clearly shown that most patients with SARS-CoV-2 infection have lymphopenia,<sup>(14)</sup> and our data are in line with Chinese findings. The lack of a control group of patients without AIH and the nature of this manuscript (case series) do not allow us to draw conclusions regarding the possible association between chronic treatment with thiopurines and the risk of developing COVID-19. Whether it would be sensible to stop thiopurines and increase steroids in patients with COVID-19 treated with immunosuppression is difficult to be ascertained, and more evidence is needed. One should consider that it is highly likely that the immunosuppressive effect of thiopurines would not immediately cease after drug withdrawal, thanks to their mechanism of action,<sup>(15)</sup> while this is probably not true for steroids, as suggested by the early relapse occurred in case number 9. Moreover, there is well-established literature showing that patients with AIH in stable control of their disease are at high risk of relapse when they suddenly reduce/stop their immunosuppression; therefore, empirical change of immunosuppressive medications should be considered with caution,<sup>(3,16)</sup> before more evidence is available.

The main limitations of this study are the small sample size and the short follow-up, which prevent us to infer whether patients with treated AIH have a specific clinical phenotype. To answer this research question, we would need a larger sample size and longer observation. In addition, the approach toward immunosuppression was too heterogenous to draw solid conclusions, especially regarding the beneficial or detrimental role of steroids during COVID-19. Finally, this study does not allow us to understand whether patients with treated AIH are more or less prone to develop COVID-19, lacking a non-AIH control group. However, because COVID-19 is a rapidly evolving epidemic that is affecting countries with different time frames, we believe our data are timely and could be of value for clinicians.

COVID-19 in patients with AIH treated with immunosuppression appears to have a disease course presumptively similar to the general population. We believe that empirical reduction of immunosuppression in patients with AIH (and, by extension, other autoimmune conditions) during COVID-19 might be harmful, as it could expose individuals to a higher risk of relapse of the disease.<sup>(3)</sup> Moreover, for most immunosuppressive drugs, the immunosuppressant effect would take weeks before disappearing. Up until now, a case-by-case approach is warranted, adopting clinical judgement until more data are collected and can guide the management of these challenging cases.

## REFERENCES

- 1) Livingston E, Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. *JAMA* 2020 Mar 17. <https://doi.org/10.1001/jama.2020.4344>. [Epub ahead of print]
- 2) Krawitt EL. Autoimmune hepatitis. *N Engl J Med* 2006;354:54-66.
- 3) Van Gerven NMF, Verwer BJ, Witte BI, Van Hoek B, Coenraad MJ, Van Erpecum KJ, et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. *J Hepatol* 2013;58:141-147.
- 4) Kirchgerner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-spira R. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. *Gastroenterology* 2018;155:337-346.e10.
- 5) Kaltsas A, Sepkowitz K. Community acquired respiratory and gastrointestinal viral infections: challenges in the immunocompromised host. *Curr Opin Infect Dis* 2012;25:423-430.
- 6) Hui DS, Azhar EI, Kim Y-J, Memish ZA, Oh M, Zumla A. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. *Lancet Infect Dis* 2018;18:e217-e227.
- 7) European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. *J Hepatol* 2018;69:406-460. <https://doi.org/10.1016/j.jhep.2018.03.024>.
- 8) Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 2020;6736:19-20.
- 9) Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med* 2020;46:846-848.
- 10) Ge Y, Tian T, Huang S, Wan F, Li J, Li S, et al. A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. *bioRxiv* 2020. <https://doi.org/10.1101/2020.03.11.986836>.
- 11) Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. *Lancet Infect Dis* 2020. [https://doi.org/10.1016/S1473-3099\(20\)30132-8](https://doi.org/10.1016/S1473-3099(20)30132-8).
- 12) Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. *Cell Discov* 2020;6:14.
- 13) Vögelin M, Biedermann L, Frei P, Vavricka SR, Scharl S, Zeitz J, et al. The impact of azathioprine-associated lymphopenia on the onset of opportunistic infections in patients with inflammatory bowel disease. *PLoS One* 2016;11:e0155218.
- 14) Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020. <https://doi.org/10.1056/NEJMoa2002032>.
- 15) Bayoumy AB, Simsek M, Seinen ML, Mulder CJJ, Ansari A, Peters GJ, et al. The continuous rediscovery and the benefit-risk ratio of thioguanine, a comprehensive review. *Expert Opin Drug Metab Toxicol* 2020;16:111-123.
- 16) Montano-loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. *Liver Int* 2007;27:507-515.